骨质疏松中不同炎症因子的研究进展
Research Progress of Different Inflammatory Factors in Osteoporosis
DOI: 10.12677/ACM.2022.124373, PDF,    科研立项经费支持
作者: 卢 锋:浙江大学医学院,浙江 杭州;陈海啸*:浙江大学附属台州医院,浙江 临海
关键词: 骨质疏松炎症因子炎症性疾病破骨细胞RANKLOsteoporosis Inflammatory Factors Inflammatory Diseases Osteoclasts RANKL
摘要: 大量研究表明炎性细胞因子对各种炎性疾病发挥重要作用,但对其具体作用的报道并不总是一致的。它们可用作指示或监测疾病或其进展的生物标志物,也可用作治疗的临床适用参数。免疫系统的各种炎症因子可以上调核因子-κB受体活化因子配体(Receptor Activator for Nuclear Factor-κB Ligand, RANKL)的表达,RANKL与破骨细胞前体细胞的RANK结合促进破骨细胞的分化和活化,最终引起炎症性骨质疏松的发生发展。但迄今为止,炎症因子对骨质疏松的具体影响机制一直没有得到系统地归纳。因此,在这篇综述中,我们筛选总结了炎症因子白介素-1 (Interleukin-1, IL-1)、IL-33、IL-6、IL-8、IL-10和肿瘤坏死因子-α (tumor necrosis factor-α, TNF-α)的生物学信息在炎症和骨质疏松中的作用,为炎症性骨质疏松提供了一个系统的理论基础。
Abstract: A large number of studies have shown that inflammatory cytokines play an important role in various inflammatory diseases, but the reports on their specific effects are not always consistent. They can be used as biomarkers to indicate or monitor the disease or its progress, and can also be used as clinical parameters for treatment. Various inflammatory factors in the immune system can up-regulate the expression of nuclear factor-kappa B receptor activating factor ligand (Receptor Activator for Nuclear Factor-κB Ligand, RANKL). The binding of RANKL to the RANK of osteoclast precursors promotes the differentiation and activation of osteoclasts, resulting in the occurrence and development of inflammatory osteoporosis. But so far, the specific mechanism of inflammatory factors on osteoporosis has not been systematically summarized. Therefore, in this review, we screened and summarized the biological information of inflammatory factors interleukin-1 (Interleukin-1, IL-1), IL-33, IL-6, IL-8, IL-10 and tumor necrosis factor-α (tumor necrosis factor-α, TNF-α) and their roles in inflammation and osteoporosis, which provided a systematic theoretical basis for inflammatory osteoporosis.
文章引用:卢锋, 陈海啸. 骨质疏松中不同炎症因子的研究进展[J]. 临床医学进展, 2022, 12(4): 2590-2604. https://doi.org/10.12677/ACM.2022.124373

参考文献

[1] Ensrud, K.E. and Crandall, C.J. (2017) Osteoporosis. Annals of Internal Medicine, 167, ITC17-ITC32. [Google Scholar] [CrossRef
[2] Johnston, C.B. and Dagar, M. (2020) Osteoporosis in Older Adults. The Medical clinics of North America, 104, 873-884. [Google Scholar] [CrossRef] [PubMed]
[3] Cotts, K.G. and Cifu, A.S. (2018) Treatment of Osteoporosis. JAMA, 319, 1040-1041. [Google Scholar] [CrossRef] [PubMed]
[4] Zhong, D., Xu, G.-Z., Wu, J.-Z., et al. (2021) Circ-ITCH Sponges miR-214 to Promote the Osteogenic Differentiation in Osteoporosis via Upregulating YAP1. Cell Death & Disease, 12, Article No. 340. [Google Scholar] [CrossRef] [PubMed]
[5] Jin, F., Li, J., Zhang, Y.-B., et al. (2021) A functional Motif of Long Noncoding RNA Nron against Osteoporosis. Nature Communications, 12, Article No. 3319. [Google Scholar] [CrossRef] [PubMed]
[6] Hosseinkhani, B., van den Akker, N.M.S., Molin, D.G.M., et al. (2020) (Sub)Populations of Extracellular Vesicles Released by TNF-α -Triggered Human Endothelial Cells Promote Vascular Inflammation and Monocyte Migration. Journal of Extracellular Vesicles, 9, Article ID: 1801153. [Google Scholar] [CrossRef] [PubMed]
[7] Yao, F., Xue, Q., Li, K., et al. (2019) Phenolic Compounds and Ginsenosides in Ginseng Shoots and Their Antioxidant and Anti-Inflammatory Capacities in LPS-Induced RAW264.7 Mouse Macrophages. International Journal of Molecular Sciences, 20, Article No. 2951. [Google Scholar] [CrossRef] [PubMed]
[8] Zhu, N. and Hou, J. (2021) Molecular Mechanism of the Anti-Inflammatory Effects of Sophorae Flavescentis Aiton identified by network pharmacology. Scientific Reports, 11, Article No. 1005. [Google Scholar] [CrossRef] [PubMed]
[9] Kany, S., Vollrath, J.T. and Relja, B. (2019) Cytokines in Inflammatory Disease. International Journal of Molecular sciences, 20, Article No. 6008. [Google Scholar] [CrossRef] [PubMed]
[10] Besedovsky, L., Lange, T. and Haack, M. (2019) The Sleep-Immune Crosstalk in Health and Disease. Physiological Reviews, 99, 1325-1380. [Google Scholar] [CrossRef] [PubMed]
[11] Coussens, L.M. and Werb, Z. (2002) Inflammation and Cancer. Nature, 420, 860-867. [Google Scholar] [CrossRef] [PubMed]
[12] Campisi, J. (2005) Senescent Cells, Tumor Suppression, and Organismal Aging: Good Citizens, Bad Neighbors. Cell, 120, 513-522. [Google Scholar] [CrossRef] [PubMed]
[13] Mantovani, A., Allavena, P., Sica, A., et al. (2008) Cancer-Related Inflammation. Nature, 454, 436-444. [Google Scholar] [CrossRef] [PubMed]
[14] Kuilman, T., Michaloglou, C., Vredeveld, L.C.W., et al. (2008) Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network. Cell, 133, 1019-1031. [Google Scholar] [CrossRef] [PubMed]
[15] Acosta, J.C., O’Loghlen, A., Banito, A., et al. (2008) Chemokine Signaling via the CXCR2 Receptor Reinforces Senescence. Cell, 133, 1006-1018. [Google Scholar] [CrossRef] [PubMed]
[16] Grivennikov, S.I., Greten, F.R. and Karin, M. (2010) Immunity, Inflammation, and Cancer. Cell, 140, 883-899. [Google Scholar] [CrossRef] [PubMed]
[17] Murakami, M., Harada, M., Kamimura, D., et al. (2013) Disease-Association Analysis of an Inflammation-Related Feedback Loop. Cell Reports, 3, 946-959. [Google Scholar] [CrossRef] [PubMed]
[18] Napimoga, M.H., Dantas Formiga, W.D., Abdalla, H.B., et al. (2020) Secreted Osteoclastogenic Factor of Activated T Cells (SOFAT) Is Associated With Rheumatoid Arthritis and Joint Pain: Initial Evidences of a New Pathway. Frontiers in Immunology, 11, Article No. 1442. [Google Scholar] [CrossRef] [PubMed]
[19] Liu, Y., Wang, Z., Ma, C., et al. (2020) Dracorhodin Perchlorate Inhibits Osteoclastogenesis through Repressing Rankl-Stimulated Nfatc1 Activity. Journal of Cellular and Molecular Medicine, 24, 3303-3313. [Google Scholar] [CrossRef] [PubMed]
[20] Saylor, P.J., Lee, R.J. and Smith, M.R. (2011) Emerging Therapies to Prevent Skeletal Morbidity in Men with Prostate Cancer. Journal of Clinical Oncology, 29, 3705-3714. [Google Scholar] [CrossRef
[21] Dinarello, C.A. and Wolff, S.M. (1993) The Role of Interleukin-1 in Disease. The New England Journal of Medicine, 328, 106-113. [Google Scholar] [CrossRef
[22] Borish, L.C. and Steinke, J.W. (2003) 2. Cytokines and Chemokines. The Journal of Allergy and Clinical Immunology, 111, S460-S475. [Google Scholar] [CrossRef] [PubMed]
[23] Dinarello, C.A. (2011) Interleukin-1 in the Pathogenesis and Treatment of Inflammatory Diseases. Blood, 117, 3720-3732. [Google Scholar] [CrossRef] [PubMed]
[24] Cerretti, D.P., Kozlosky, C.J., Mosley, B., et al. (1992) Molecular Cloning of the Interleukin-1 Beta Converting Enzyme. Science, 256, 97-100. [Google Scholar] [CrossRef] [PubMed]
[25] Pichery, M., Mirey, E., Mercier, P., et al. (2012) Endogenous IL-33 Is Highly Expressed in Mouse Epithelial Barrier Tissues, Lymphoid Organs, Brain, Embryos, and Inflamed Tissues: In Situ Analysis Using a Novel Il-33-LacZ Gene Trap Reporter Strain. Journal of Immunology, 188, 3488-3495. [Google Scholar] [CrossRef] [PubMed]
[26] Schmitz, J., Owyang, A., Oldham, E., et al. (2005) IL-33, an Interleukin-1-Like Cytokine That Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines. Immunity, 23, 479-490. [Google Scholar] [CrossRef] [PubMed]
[27] McCarthy, D.A., Ranganathan, A., Subbaram, S., et al. (2013) Redox-Control of the Alarmin, Interleukin-1α. Redox Biology, 1, 218-225. [Google Scholar] [CrossRef] [PubMed]
[28] Kim, B., Lee, Y., Kim, E., et al. (2013) The Interleukin-1α Precursor is Biologically Active and Is Likely a Key Alarmin in the IL-1 Family of Cytokines. Frontiers in Immunology, 4, Article No. 391. [Google Scholar] [CrossRef] [PubMed]
[29] Gross, O., Yazdi, A.S., Thomas, C.J., et al. (2012) Inflammasome Activators Induce Interleukin-1α Secretion via Distinct Pathways with Differential Requirement for the Protease Function of Caspase-1. Immunity, 36, 388-400. [Google Scholar] [CrossRef] [PubMed]
[30] Liu, X., Zhang, Z., Ruan, J., et al. (2016) Inflammasome-Activated Gasdermin D Causes Pyroptosis by Forming Membrane Pores. Nature, 535, 153-158. [Google Scholar] [CrossRef] [PubMed]
[31] Sborgi, L., Rühl, S., Mulvihill, E., et al. (2016) GSDMD Membrane Pore Formation Constitutes the Mechanism of Pyroptotic Cell Death. The EMBO Journal, 35, 1766-1778. [Google Scholar] [CrossRef] [PubMed]
[32] Shi, J., Zhao, Y., Wang, K., et al. (2015) Cleavage of GSDMD by Inflammatory Caspases Determines Pyroptotic Cell Death. Nature, 526, 660-665. [Google Scholar] [CrossRef] [PubMed]
[33] Zheng, Y., Humphry, M., Maguire, J.J., et al. (2013) Intracellular Interleukin-1 Receptor 2 Binding Prevents Cleavage and Activity of Interleukin-1α, Controlling Necrosis-Induced Sterile Inflammation. Immunity, 38, 285-295. [Google Scholar] [CrossRef] [PubMed]
[34] Dinarello, C.A. (2009) Immunological and Inflammatory Functions of the Interleukin-1 Family. Annual Review of Immunology, 27, 519-550. [Google Scholar] [CrossRef] [PubMed]
[35] Netea, M.G., Nold-Petry, C.A., Nold, M.F., et al. (2009) Differential Requirement for the Activation of the Inflammasome for Processing and Release of IL-1beta in Monocytes and Macrophages. Blood, 113, 2324-2335. [Google Scholar] [CrossRef] [PubMed]
[36] Agostini, L., Martinon, F., Burns, K., et al. (2004) NALP3 Forms an IL-1beta-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder. Immunity, 20, 319-325. [Google Scholar] [CrossRef
[37] Weber, A., Wasiliew, P. and Kracht, M. (2010) Interleukin-1 (IL-1) Pathway. Science Signaling, 3, cm1. [Google Scholar] [CrossRef] [PubMed]
[38] Di Paolo, N.C., Shafiani, S., Day, T., et al. (2015) Interdependence between Interleukin-1 and Tumor Necrosis Factor Regulates TNF-Dependent Control of Mycobacterium tuberculosis Infection. Immunity, 43, 1125-1136. [Google Scholar] [CrossRef] [PubMed]
[39] Bersudsky, M., Luski, L., Fishman, D., et al. (2014) Non-Redundant Properties of IL-1α and IL-1β during Acute Colon Inflammation in Mice. Gut, 63, 598-609. [Google Scholar] [CrossRef] [PubMed]
[40] Freigang, S., Ampenberger, F., Weiss, A., et al. (2013) Fatty Acid-Induced Mitochondrial Uncoupling Elicits Inflammasome-Independent IL-1α and Sterile Vascular Inflammation in Atherosclerosis. Nature Immunology, 14, 1045-1053. [Google Scholar] [CrossRef] [PubMed]
[41] Brough, D. and Denes, A. (2015) Interleukin-1α and Brain Inflammation. IUBMB Life, 67, 323-330. [Google Scholar] [CrossRef] [PubMed]
[42] Garlanda, C., Dinarello, C.A. and Mantovani, A. (2013) The Interleukin-1 Family: Back to the Future. Immunity, 39, 1003-1018. [Google Scholar] [CrossRef] [PubMed]
[43] Ge, Y., Huang, M. and Yao, Y.-M. (2019) Recent Advances in the Biology of IL-1 Family Cytokines and Their Potential Roles in Development of Sepsis. Cytokine & Growth Factor Reviews, 45, 24-34. [Google Scholar] [CrossRef] [PubMed]
[44] Teitelbaum, S.L. (2000) Bone Resorption by Osteoclasts. Science, 289, 1504-1508. [Google Scholar] [CrossRef] [PubMed]
[45] Nakamura, I. and Jimi, E. (2006) Regulation of Osteoclast Differentiation and Function by Interleukin-1. Vitamins and Hormones, 74, 357-370. [Google Scholar] [CrossRef
[46] Zupan, J., Komadina, R. and Marc, J. (2012) The Relationship between Osteoclastogenic and Anti-Osteoclastogenic Pro-Inflammatory Cytokines Differs in Human Osteoporotic and Osteoarthritic Bone Tissues. Journal of Biomedical Science, 19, Article No. 28. [Google Scholar] [CrossRef] [PubMed]
[47] Kudo, O., Fujikawa, Y., Itonaga, I., et al. (2002) Proinflammatory Cytokine (TNFalpha/IL-1alpha) Induction of Human Osteoclast Formation. The Journal of Pathology, 198, 220-227. [Google Scholar] [CrossRef] [PubMed]
[48] Lacativa, P.G.S. and Farias, M.L.F.d. (2010) Osteoporosis and Inflammation. Arquivos Brasileiros de Endocrinologia e Metabologia, 54, 123-132. [Google Scholar] [CrossRef
[49] Kim, J.H., Jin, H.M., Kim, K., et al. (2009) The Mechanism of Osteoclast Differentiation Induced by IL-1. Journal of immunology, 183, 1862-1870. [Google Scholar] [CrossRef] [PubMed]
[50] Zwerina, J., Redlich, K., Polzer, K., et al. (2007) TNF-Induced Structural Joint Damage Is Mediated by IL-1. Proceedings of the National Academy of Sciences of the United States of America, 104, 11742-11747. [Google Scholar] [CrossRef] [PubMed]
[51] Weitzmann, M.N. and Pacifici, R. (2005) The Role of T Lymphocytes in Bone Metabolism. Immunological Reviews, 208, 154-168. [Google Scholar] [CrossRef] [PubMed]
[52] Guo, C., Yang, X.-G., Wang, F., et al. (2016) IL-1α Induces Apoptosis and Inhibits the Osteoblast Differentiation of MC3T3-E1 Cells through the JNK and p38 MAPK Pathways. International Journal of Molecular Medicine, 38, 319-327. [Google Scholar] [CrossRef] [PubMed]
[53] Speziani, C., Rivollier, A., Gallois, A., et al. (2007) Murine Dendritic Cell Transdifferentiation into Osteoclasts Is Differentially Regulated by Innate and Adaptive Cytokines. European Journal of Immunology, 37, 747-757. [Google Scholar] [CrossRef] [PubMed]
[54] Carriere, V., Roussel, L., Ortega, N., et al. (2007) IL-33, the IL-1-like cytokine ligand for ST2 Receptor, Is a Chromatin-Associated Nuclear Factor in Vivo. Proceedings of the National Academy of Sciences of the United States of America, 104, 282-287. [Google Scholar] [CrossRef] [PubMed]
[55] Molofsky, A.B., Savage, A.K. and Locksley, R.M. (2015) Interleukin-33 in Tissue Homeostasis, Injury, and Inflammation. Immunity, 42, 1005-1019. [Google Scholar] [CrossRef] [PubMed]
[56] Catalan-Dibene, J., McIntyre, L.L. and Zlotnik, A. (2018) Interleukin 30 to Interleukin 40. Journal of Interferon & Cytokine Research, 38, 423-439. [Google Scholar] [CrossRef] [PubMed]
[57] Dattagupta, A. and Immaneni, S. (2018) ST2: Current Status. Indian Heart Journal, 70, S96-S101. [Google Scholar] [CrossRef] [PubMed]
[58] Villarreal, D.O. and Weiner, D.B. (2014) Interleukin 33: A Switch-Hitting Cytokine. Current Opinion in Immunology, 28, 102-106. [Google Scholar] [CrossRef] [PubMed]
[59] Lin, W., Zhou, Q., Liu, C., et al. (2017) Increased Plasma IL-17, IL-31, and IL-33 Levels in Chronic Spontaneous Urticaria. Scientific Reports, 7, Article No. 17797. [Google Scholar] [CrossRef] [PubMed]
[60] Perrigoue, J.G., Li, J., Zaph, C., et al. (2007) IL-31-IL-31R Interactions Negatively Regulate Type 2 Inflammation in the Lung. The Journal of Experimental Medicine, 204, 481-487. [Google Scholar] [CrossRef] [PubMed]
[61] Guarneri, F., Minciullo, P.L., Mannucci, C., et al. (2015) IL-31 and IL-33 Circulating Levels in Allergic Contact Dermatitis. European Annals of Allergy and Clinical Immunology, 47, 156-158.
[62] Murdaca, G., Greco, M., Tonacci, A., et al. (2019) IL-33/IL-31 Axis in Immune-Mediated and Allergic Diseases. International Journal of Molecular Sciences, 20, Article No. 5856. [Google Scholar] [CrossRef] [PubMed]
[63] Zeng, X., Zhang, Z., Gao, Q.-Q., et al. (2016) Clinical Significance of Serum Interleukin-31 and Interleukin-33 Levels in Patients of Endometrial Cancer: A Case Control Study. Disease Markers, 2016, Article ID: 9262919. [Google Scholar] [CrossRef] [PubMed]
[64] Miller, A.M. (2011) Role of IL-33 in Inflammation and Disease. Journal of Inflammation, 8, Article No. 22. [Google Scholar] [CrossRef] [PubMed]
[65] Macari, S., Madeira, M.F.M., Lima, I.L.A., et al. (2018) ST2 Regulates Bone Loss in a Site-Dependent and Estrogen-Dependent Manner. Journal of Cellular Biochemistry, 119, 8511-8521. [Google Scholar] [CrossRef] [PubMed]
[66] Hirano, T. (1998) Interleukin 6 and Its Receptor: Ten Years Later. International Reviews of Immunology, 16, 249-284. [Google Scholar] [CrossRef] [PubMed]
[67] Hunter, C.A. and Jones, S.A. (2015) IL-6 as a Keystone Cytokine in Health and Disease. Nature Immunology, 16, 448-457. [Google Scholar] [CrossRef] [PubMed]
[68] Hasegawa, H., Mizoguchi, I., Chiba, Y., et al. (2016) Expanding Diversity in Molecular Structures and Functions of the IL-6/IL-12 Heterodimeric Cytokine Family. Frontiers in Immunology, 7, Article No. 479. [Google Scholar] [CrossRef] [PubMed]
[69] Schaper, F. and Rose-John, S. (2015) Interleukin-6: Biology, Signaling and Strategies of Blockade. Cytokine & Growth Factor Reviews, 26, 475-487. [Google Scholar] [CrossRef] [PubMed]
[70] Hibi, M., Murakami, M., Saito, M., et al. (1990) Molecular Cloning and Expression of an IL-6 Signal Transducer, gp130. Cell, 63, 1149-1157. [Google Scholar] [CrossRef] [PubMed]
[71] Heinrich, P.C., Behrmann, I., Haan, S., et al. (2003) Principles of Interleukin (IL)-6-Type Cytokine Signalling and Its Regulation. The Biochemical Journal, 374, 1-20. [Google Scholar] [CrossRef] [PubMed]
[72] Radtke, S., Wüller, S., Yang, X.-P., et al. (2010) Cross-Regulation of Cytokine Signalling: Pro-Inflammatory Cytokines Restrict IL-6 Signalling through Receptor Internalisation and Degradation. Journal of Cell Science, 123, 947-959. [Google Scholar] [CrossRef] [PubMed]
[73] Boulanger, M.J., Chow, D.-C., Brevnova, E.E., et al. (2003) Hexameric Structure and Assembly of the Interleukin-6/IL-6 Alpha-Receptor/gp130 Complex. Science, 300, 2101-2104. [Google Scholar] [CrossRef] [PubMed]
[74] Franchimont, N., Lambert, C., Huynen, P., et al. (2005) Interleukin-6 Receptor Shedding Is Enhanced by Interleukin-1beta and Tumor Necrosis Factor Alpha and Is Partially Mediated by Tumor Necrosis Factor Alpha-Converting Enzyme in Osteoblast-Like Cells. Arthritis and Rheumatism, 52, 84-93. [Google Scholar] [CrossRef] [PubMed]
[75] Walev, I., Vollmer, P., Palmer, M., et al. (1996) Pore-Forming Toxins Trigger Shedding of Receptors for Interleukin 6 and Lipopolysaccharide. Proceedings of the National Academy of Sciences of the United States of America, 93, 7882-7887. [Google Scholar] [CrossRef] [PubMed]
[76] Lust, J.A., Donovan, K.A., Kline, M.P., et al. (1992) Isolation of an mRNA Encoding a Soluble Form of the Human Interleukin-6 Receptor. Cytokine, 4, 96-100. [Google Scholar] [CrossRef
[77] Rose-John, S. (2018) Interleukin-6 Family Cytokines. Cold Spring Harbor Perspectives in Biology, 10, Article No. a028415. [Google Scholar] [CrossRef] [PubMed]
[78] Luna, J.M., Moon, Y.P., Liu, K.M., et al. (2014) High-Sensitivity C-Reactive Protein and Interleukin-6-Dominant Inflammation and Ischemic Stroke Risk: The Northern Manhattan Study. Stroke, 45, 979-987. [Google Scholar] [CrossRef
[79] Atsumi, T., Singh, R., Sabharwal, L., et al. (2014) Inflammation Amplifier, a New Paradigm in Cancer Biology. Cancer Research, 74, 8-14. [Google Scholar] [CrossRef
[80] Hirano, T. and Murakami, M. (2020) COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome. Immunity, 52, 731-733. [Google Scholar] [CrossRef] [PubMed]
[81] Hirano, T. (2010) Interleukin 6 in Autoimmune and Inflammatory Diseases: A Personal Memoir. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 86, 717-730. [Google Scholar] [CrossRef] [PubMed]
[82] Grivennikov, S.I. and Karin, M. (2010) Dangerous Liaisons: STAT3 and NF-kappaB Collaboration and Crosstalk in Cancer. Cytokine & Growth Factor Reviews, 21, 11-19. [Google Scholar] [CrossRef] [PubMed]
[83] Grupp, S.A., Kalos, M., Barrett, D., et al. (2013) Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia. The New England Journal of Medicine, 368, 1509-1518. [Google Scholar] [CrossRef
[84] Heinrich, P.C., Castell, J.V. and Andus, T. (1990) Interleukin-6 and the Acute Phase Response. The Biochemical Journal, 265, 621-636. [Google Scholar] [CrossRef] [PubMed]
[85] Gillmore, J.D., Lovat, L.B., Persey, M.R., et al. (2001) Amyloid Load and Clinical Outcome in AA Amyloidosis in Relation to Circulating Concentration of Serum Amyloid A Protein. Lancet, 358, 24-29. [Google Scholar] [CrossRef
[86] Korn, T., Bettelli, E., Oukka, M., et al. (2009) IL-17 and Th17 Cells. Annual Review of Immunology, 27, 485-517. [Google Scholar] [CrossRef] [PubMed]
[87] Bettelli, E., Carrier, Y., Gao, W., et al. (2006) Reciprocal Developmental Pathways for the Generation of Pathogenic Effector TH17 and Regulatory T Cells. Nature, 441, 235-238. [Google Scholar] [CrossRef] [PubMed]
[88] Kimura, A. and Kishimoto, T. (2010) IL-6: Regulator of Treg/Th17 Balance. European Journal of Immunology, 40, 1830-1835. [Google Scholar] [CrossRef] [PubMed]
[89] Hashizume, M., Hayakawa, N. and Mihara, M. (2008) IL-6 Trans-Signalling Directly Induces RANKL on Fibroblast-Like Synovial Cells and Is Involved in RANKL Induction by TNF-alpha and IL-17. Rheumatology, 47, 1635-1640. [Google Scholar] [CrossRef] [PubMed]
[90] Kotake, S., Sato, K., Kim, K.J., et al. (1996) Interleukin-6 and Soluble Interleukin-6 Receptors in the Synovial Fluids from Rheumatoid Arthritis Patients Are Responsible for Osteoclast-Like Cell Formation. Journal of Bone and Mineral Research, 11, 88-95. [Google Scholar] [CrossRef] [PubMed]
[91] Poli, V., Balena, R., Fattori, E., et al. (1994) Interleukin-6 Deficient Mice Are Protected from Bone Loss Caused by Estrogen Depletion. The EMBO Journal, 13, 1189-1196. [Google Scholar] [CrossRef] [PubMed]
[92] Palmqvist, P., Persson, E., Conaway, H.H., et al. (2002) IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-kappa B Ligand, Osteoprotegerin, and Receptor Activator of NF-kappa B in Mouse Calvariae. Journal of Immunology, 169, 3353-3362. [Google Scholar] [CrossRef] [PubMed]
[93] Wong, P.K.K., Quinn, J.M.W., Sims, N.A., et al. (2006) Interleukin-6 Modulates Production of T Lymphocyte-Derived Cytokines in Antigen-Induced Arthritis and Drives Inflammation-Induced Osteoclastogenesis. Arthritis and Rheumatism, 54, 158-168. [Google Scholar] [CrossRef] [PubMed]
[94] Feng, W., Liu, H., Luo, T., et al. (2017) Combination of IL-6 and sIL-6R Differentially Regulate Varying Levels of RANKL-Induced Osteoclastogenesis through NF-κB, ERK and JNK Signaling Pathways. Scientific Reports, 7, Article No. 41411. [Google Scholar] [CrossRef] [PubMed]
[95] De Benedetti, F., Rucci, N., Del Fattore, A., et al. (2006) Impaired Skeletal Development in Interleukin-6-Transgenic Mice: A Model for the Impact of Chronic Inflammation on the Growing Skeletal System. Arthritis and Rheumatism, 54, 3551-3563. [Google Scholar] [CrossRef] [PubMed]
[96] Brat, D.J., Bellail, A.C. and Van Meir, E.G. (2005) The Role of Interleukin-8 and Its Receptors in Gliomagenesis and Tumoral Angiogenesis. Neuro-Oncology, 7, 122-133. [Google Scholar] [CrossRef
[97] Waugh, D.J.J. and Wilson, C. (2008) The Interleukin-8 Pathway in Cancer. Clinical Cancer Research, 14, 6735-6741. [Google Scholar] [CrossRef
[98] Holmes, W.E., Lee, J., Kuang, W.J., et al. (1991) Structure and Functional Expression of a Human Interleukin-8 Receptor. Science, 253, 1278-1280. [Google Scholar] [CrossRef] [PubMed]
[99] Murphy, P.M. and Tiffany, H.L. (1991) Cloning of Complementary DNA Encoding a Functional Human Interleukin-8 Receptor. Science, 253, 1280-1283. [Google Scholar] [CrossRef] [PubMed]
[100] Knall, C., Young, S., Nick, J.A., et al. (1996) Interleukin-8 Regulation of the Ras/Raf/Mitogen-Activated Protein Kinase Pathway in Human Neutrophils. The Journal of Biological Chemistry, 271, 2832-2838. [Google Scholar] [CrossRef] [PubMed]
[101] MacManus, C.F., Pettigrew, J., Seaton, A., et al. (2007) Interleukin-8 Signaling Promotes Translational Regulation of Cyclin D in Androgen-Independent Prostate Cancer Cells. Molecular Cancer Research, 5, 737-748. [Google Scholar] [CrossRef
[102] Venkatakrishnan, G., Salgia, R. and Groopman, J.E. (2000) Chemokine Receptors CXCR-1/2 Activate Mitogen-Activated Protein Kinase via the Epidermal Growth Factor Receptor in Ovarian Cancer Cells. The Journal of Biological Chemistry, 275, 6868-6875. [Google Scholar] [CrossRef] [PubMed]
[103] Luppi, F., Longo, A.M., de Boer, W.I., et al. (2007) Interleukin-8 Stimulates Cell Proliferation in Non-Small Cell Lung Cancer through Epidermal Growth Factor Receptor Transactivation. Lung Cancer, 56, 25-33. [Google Scholar] [CrossRef] [PubMed]
[104] Glynn, P.C., Henney, E. and Hall, I.P. (2002) The Selective CXCR2 Antagonist SB272844 Blocks Interleukin-8 and Growth-Related Oncogene-Alpha-Mediated Inhibition of Spontaneous Neutrophil Apoptosis. Pulmonary Pharmacology & Therapeutics, 15, 103-110. [Google Scholar] [CrossRef] [PubMed]
[105] Li, A., Dubey, S., Varney, M.L., et al. (2003) IL-8 Directly Enhanced Endothelial Cell Survival, Proliferation, and Matrix Metalloproteinases Production and Regulated Angiogenesis. Journal of Immunology, 170, 3369-3376. [Google Scholar] [CrossRef] [PubMed]
[106] Murphy, C., McGurk, M., Pettigrew, J., et al. (2005) Nonapical and Cytoplasmic Expression of Interleukin-8, CXCR1, and CXCR2 Correlates with Cell Proliferation and Microvessel Density in Prostate Cancer. Clinical Cancer Research, 11, 4117-4127. [Google Scholar] [CrossRef
[107] Allen, T.C. and Kurdowska, A. (2014) Interleukin 8 and Acute Lung Injury. Archives of pathology & Laboratory Medicine, 138, 266-269. [Google Scholar] [CrossRef
[108] Kobayashi, Y. (2008) The Role of Chemokines in Neutrophil Biology. Frontiers in Bioscience, 13, 2400-2407. [Google Scholar] [CrossRef] [PubMed]
[109] Ning, Y., Manegold, P.C., Hong, Y.K., et al. (2011) Interleukin-8 Is Associated with Proliferation, Migration, Angiogenesis and Chemosensitivity in Vitro and in Vivo in Colon Cancer Cell Line Models. International Journal of Cancer, 128, 2038-2049. [Google Scholar] [CrossRef] [PubMed]
[110] Kraft, R., Herndon, D.N., Finnerty, C.C., et al. (2015) Predictive Value of IL-8 for Sepsis and Severe Infections after Burn Injury: A Clinical Study. Shock, 43, 222-227. [Google Scholar] [CrossRef
[111] Al-Daghri, N.M., Yakout, S., Al-Shehri, E., et al. (2014) Inflammatory and Bone Turnover Markers in Relation to PTH and Vitamin D Status among Saudi Postmenopausal Women with and without Osteoporosis. International Journal of Clinical and Experimental Medicine, 7, 3528-3535.
[112] Sousa, L.H., Linhares, E.V.M., Alexandre, J.T., et al. (2016) Effects of Atorvastatin on Periodontitis of Rats Subjected to Glucocorticoid-Induced Osteoporosis. Journal of Periodontology, 87, 1206-1216. [Google Scholar] [CrossRef] [PubMed]
[113] Hu, X., Sun, Y., Xu, W., et al. (2017) Expression of RANKL by Peripheral Neutrophils and Its Association with Bone Mineral Density in COPD. Respirology, 22, 126-132. [Google Scholar] [CrossRef] [PubMed]
[114] Ouyang, W. and O’Garra, A. (2019) IL-10 Family Cytokines IL-10 and IL-22: From Basic Science to Clinical Translation. Immunity, 50, 871-891. [Google Scholar] [CrossRef] [PubMed]
[115] Moore, K.W., Vieira, P., Fiorentino, D.F., et al. (1990) Homology of Cytokine Synthesis Inhibitory Factor (IL-10) to the Epstein-Barr Virus Gene BCRFI. Science, 248, 1230-1234. [Google Scholar] [CrossRef] [PubMed]
[116] Moore, K.W., O’Garra, A., de Waal Malefyt, R., et al. (1993) Interleukin-10. Annual Review of Immunology, 11, 165-190. [Google Scholar] [CrossRef] [PubMed]
[117] Moore, K.W., de Waal Malefyt, R., Coffman, R.L., et al. (2001) Interleukin-10 and the Interleukin-10 Receptor. Annual Review of Immunology, 19, 683-765. [Google Scholar] [CrossRef] [PubMed]
[118] Vieira, P., de Waal-Malefyt, R., Dang, M.N., et al. (1991) Isolation and Expression of Human Cytokine Synthesis Inhibitory Factor cDNA Clones: Homology to Epstein-Barr Virus Open Reading Frame BCRFI. Proceedings of the National Academy of Sciences of the United States of America, 88, 1172-1176. [Google Scholar] [CrossRef] [PubMed]
[119] Ouyang, W., Rutz, S., Crellin, N.K., et al. (2011) Regulation and functions of the IL-10 family of Cytokines in Inflammation and Disease. Annual Review of Immunology, 29, 71-109. [Google Scholar] [CrossRef] [PubMed]
[120] Sing, A., Rost, D., Tvardovskaia, N., et al. (2002) Yersinia V-Antigen Exploits Toll-Like Receptor 2 and CD14 for Interleukin 10-Mediated Immunosuppression. The Journal of Experimental Medicine, 196, 1017-1024. [Google Scholar] [CrossRef] [PubMed]
[121] Dresner-Pollak, R., Gelb, N., Rachmilewitz, D., et al. (2004) Interleukin 10-Deficient Mice Develop Osteopenia, Decreased Bone Formation, and Mechanical Fragility of Long Bones. Gastroenterology, 127, 792-801. [Google Scholar] [CrossRef] [PubMed]
[122] Rios-Arce, N.D., Dagenais, A., Feenstra, D., et al. (2020) Loss of Interleukin-10 Exacerbates Early Type-1 Diabetes-Induced Bone Loss. Journal of Cellular Physiology, 235, 2350-2365. [Google Scholar] [CrossRef] [PubMed]
[123] Salomon, B.L. (2021) Insights into the Biology and Therapeutic Implications of TNF and Regulatory T Cells. Nature Reviews. Rheumatology, 17, 487-504. [Google Scholar] [CrossRef] [PubMed]
[124] Wang, Y., Che, M., Xin, J., et al. (2020) The Role of IL-1β and TNF-α in Intervertebral Disc Degeneration. Biomedicine & Pharmacotherapy, 131, Article ID: 110660. [Google Scholar] [CrossRef] [PubMed]
[125] Bradley, J.R. (2008) TNF-Mediated Inflammatory Disease. The Journal of Pathology, 214, 149-160. [Google Scholar] [CrossRef] [PubMed]
[126] Zhang, Q., Li, Z., Zhang, M., et al. (2020) Injectable in Situ Self-Cross-Linking Hydrogels Based on Hemoglobin, Carbon Quantum Dots, and Sodium Alginate for Real-Time Detection of Wound Bacterial Infection and Efficient Postoperative Prevention of Tumor Recurrence. Langmuir, 36, 13263-13273. [Google Scholar] [CrossRef] [PubMed]
[127] Wang, T., He, C. and Yu, X. (2017) Pro-Inflammatory Cytokines: New Potential Therapeutic Targets for Obesity-Related Bone Disorders. Current Drug Targets, 18, 1664-1675. [Google Scholar] [CrossRef] [PubMed]
[128] Zhang, H., Hilton, M.J., Anolik, J.H., et al. (2014) NOTCH Inhibits Osteoblast Formation in Inflammatory Arthritis via Noncanonical NF-κB. The Journal of Clinical Investigation, 124, 3200-3214. [Google Scholar] [CrossRef
[129] Yamazaki, M., Fukushima, H., Shin, M., et al. (2009) Tumor Necrosis Factor Alpha Represses Bone Morphogenetic Protein (BMP) Signaling by Interfering with the DNA Binding of Smads through the Activation of NF-kappaB. The Journal of Biological Chemistry, 284, 35987-35995. [Google Scholar] [CrossRef
[130] Huang, H., Zhao, N., Xu, X., et al. (2011) Dose-Specific Effects of Tumor Necrosis Factor Alpha on Osteogenic Differentiation of Mesenchymal Stem Cells. Cell Proliferation, 44, 420-427. [Google Scholar] [CrossRef] [PubMed]
[131] Takayanagi, H., Kim, S. and Taniguchi, T. (2002) Signaling Crosstalk between RANKL and Interferons in Osteoclast Differentiation. Arthritis Research & Therapy, 4, Article No. S227. [Google Scholar] [CrossRef] [PubMed]
[132] Takayanagi, H., Ogasawara, K., Hida, S., et al. (2000) T-Cell-Mediated Regulation of Osteoclastogenesis by Signalling Cross-Talk between RANKL and IFN-Gamma. Nature, 408, 600-605. [Google Scholar] [CrossRef] [PubMed]
[133] Yao, Z., Lei, W., Duan, R., et al. (2017) RANKL Cytokine Enhances TNF-Induced Osteoclastogenesis Independently of TNF Receptor Associated Factor (TRAF) 6 by Degrading TRAF3 in Osteoclast Precursors. The Journal of Biological Chemistry, 292, 10169-10179. [Google Scholar] [CrossRef
[134] Kaplan, D.L., Eielson, C.M., Horowitz, M.C., et al. (1996) Tumor Necrosis Factor-Alpha Induces Transcription of the Colony-Stimulating Factor-1 Gene in Murine Osteoblasts. Journal of Cellular Physiology, 168, 199-208. [Google Scholar] [CrossRef
[135] Yao, X., Liu, M., Jin, F., et al. (2020) Comprehensive Analysis of Differentially Expressed Circular RNAs in Patients with Senile Osteoporotic Vertebral Compression Fracture. BioMed Research International, 2020, Article ID: 4951251. [Google Scholar] [CrossRef] [PubMed]